Individualized treatment of gastric cancer:Impact of molecular biology and pathohistological features

被引:3
作者
Yves Dittmar [1 ]
Utz Settmacher [1 ]
机构
[1] Department of General,Visceral and Vascular Surgery,University Hospital Jena
关键词
Gastric cancer; Molecular biology; Targeted therapy; Personalized medicine; Signaling pathway;
D O I
暂无
中图分类号
R735.2 [胃肿瘤];
学科分类号
100214 ;
摘要
Gastric cancer is one of the most common malignancies worldwide.The overall prognosis remains poor over the last decades even though improvements in surgical outcomes have been achieved.A better understanding of the molecular biology of gastric cancer and detection of eligible molecular targets might be of central interest to further improve clinical outcome.With this intention,first steps have been made in the research of growth factor signaling.Regarding morphogens,cell cycle and nuclear factor-κB signaling,a remarkable count of target-specific agents have been developed,nevertheless the transfer into the field of clinical routine is still at the beginning.The potential utility of epigenetic targets and the further evaluation of micro RNA signaling seem to have potential for the development of novel treatment strategies in the future.
引用
收藏
页码:292 / 302
页数:11
相关论文
共 34 条
[1]   Role of Notch signaling pathway in gastric cancer: A meta-analysis of the literature [J].
Xiao Du ;
Zhong Cheng ;
Yi-Han Wang ;
Zi-Heng Guo ;
Si-Qin Zhang ;
Jian-Kun Hu ;
Zong-Guang Zhou .
World Journal of Gastroenterology, 2014, (27) :9191-9199
[2]   Epigenetics: An emerging player in gastric cancer [J].
Changwon Kang ;
Ji-Joon Song ;
Jaeok Lee ;
Mi Young Kim .
World Journal of Gastroenterology, 2014, (21) :6433-6447
[3]  
Selective inhibition of cell growth by activin in SNU-16 cells[J]. Young Il Kim,Hee Joo Lee,Inkoo Khang,Byung-Nam Cho,Ha Kyu Lee.World Journal of Gastroenterology. 2006(19)
[4]   Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells [J].
Hamano, Shingo ;
Mori, Yoshinori ;
Aoyama, Mineyoshi ;
Kataoka, Hiromi ;
Tanaka, Mamoru ;
Ebi, Masahide ;
Kubota, Eiji ;
Mizoshita, Tsutomu ;
Tanida, Satoshi ;
Johnston, Randal N. ;
Asai, Kiyofumi ;
Joh, Takashi .
CANCER LETTERS, 2015, 356 (02) :846-854
[5]  
Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer[J] . Shaheenah Dawood,Bhawna Sirohi.Future Oncol. . 2015 (6)
[6]  
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)[J] . Lin Shen,Jin Li,Jianming Xu,Hongming Pan,Guanghai Dai,Shukui Qin,Liwei Wang,Jinwan Wang,Zhenzhou Yang,Yongqian Shu,Ruihua Xu,Lei Chen,Yunpeng Liu,Shiying Yu,Lilian Bu,Yongzhe Piao.Gastric Cancer . 2015 (1)
[7]  
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J] . Hansjochen Wilke,Kei Muro,Eric Van Cutsem,Sang-Cheul Oh,Gy?rgy Bodoky,Yasuhiro Shimada,Shuichi Hironaka,Naotoshi Sugimoto,Oleg Lipatov,Tae-You Kim,David Cunningham,Philippe Rougier,Yoshito Komatsu,Jaffer Ajani,Michael Emig,Roberto Carlesi,David Ferry,Kumari Chandrawansa,Jonathan D Sch
[8]  
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study[J] . Timothy Iveson,Ross C Donehower,Irina Davidenko,Sergey Tjulandin,Andrzej Deptala,Mark Harrison,Somanath Nirni,Kuntegowdanahalli Lakshmaiah,Anne Thomas,Yizhou Jiang,Min Zhu,Rui Tang,Abraham Anderson,Sarita Dubey,Kelly S Oliner,Elwyn Loh.Lancet Oncol
[9]  
FGF Receptors: Cancer Biology and Therapeutics[J] . Masaru Katoh,Hitoshi Nakagama.Med. Res. Rev. . 2014 (2)
[10]  
MicroRNAs in Gastric Cancer: From Benchtop to Bedside[J] . Fuyi Tong,Peng Cao,Yuan Yin,Suhua Xia,Rensheng Lai,Shenlin Liu.Digestive Diseases and Sciences . 2014 (1)